Filing Flows › Abbott Laboratories (ABT) › Q3 2026 › vs Q2 2026
Abbott Laboratories (ABT) Q3 2026 vs Q2 2026 (quarter over quarter)
Abbott Laboratories's revenue rose $420M (+3%) from $12.6B in Q2 2026 to $13.0B in Q3 2026. Operating margin 10.4% against 13.4% (-3.0 pts).
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 10.4% | 13.4% | -3.0 pts |
| Net margin | 7.1% | 7.4% | -0.3 pts |
| Free cash flow margin | 9.4% | 15.8% | -6.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $13.0B | $12.6B | $420M | +3% |
| Operating profit | $1.4B | $1.7B | −$335M | -20% |
| Costs & expenses | $11.7B | $10.9B | $755M | +7% |
| Pre-tax earnings | $1.2B | $1.5B | −$293M | -19% |
| Other expense, net | $127M | $169M | −$42.0M | -25% |
| Cost of revenue | $5.6B | $5.3B | $303M | +6% |
| Research & development | $920M | $892M | $28.0M | +3% |
| SG&A | $4.3B | $4.0B | $241M | +6% |
| Other operating costs | $841M | $658M | $183M | +28% |
| Net earnings | $920M | $928M | −$8.0M | -0.9% |
| Income tax | $311M | $596M | −$285M | -48% |
| Depreciation & amortization | $1.3B | $1.1B | $196M | +18% |
| Share-based compensation | $137M | $168M | −$31.0M | -18% |
| Working capital & other | $576M | −$332M | $908M | — |
| Operating cash flow | $1.7B | $2.5B | −$751M | -30% |
| Free cash flow (OCF − capex) | $1.2B | $2.0B | −$767M | -39% |
| Capital expenditures | $513M | $497M | $16.0M | +3% |
Questions
How much did Abbott Laboratories's revenue grow quarter over quarter in Q3 2026?
Abbott Laboratories's revenue rose $420M (+3%) from $12.6B in Q2 2026 to $13.0B in Q3 2026. Operating margin 10.4% against 13.4% (-3.0 pts).